Business Context and Reporting Period
Company: Stepan Company (SCL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Stepan produces intermediate chemicals used in cleaning, disinfection, construction, and food/pharmaceutical applications. Operations are organized into three segments: Surfactants (69% of H1 2024 sales), Polymers (28%), and Specialty Products (3%).
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | H1 2024 | H1 2023 |
|---|---|---|---|---|
| Net Sales | $556,405 | $579,975 | $1,107,823 | $1,231,411 |
| Gross Profit | $69,552 | $66,397 | $139,833 | $139,957 |
| Operating Income | $18,667 | $17,809 | $38,836 | $38,866 |
| Net Income | $9,521 | $12,684 | $23,414 | $28,826 |
| Diluted EPS | $0.42 | $0.55 | $1.02 | $1.25 |
| Operating Cash Flow (6mo) | $71,056 | $35,802 | ||
| Free Cash Flow (6mo) | ||||
| Total Debt | $657,058 | $654,146 | ||
| Cash & Equivalents | $124,708 | $129,823 |
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($59,867 for H1 2024).
Material Changes vs. Prior Period
- Revenue Decline: Consolidated net sales decreased 4% in Q2 and 10% in H1 2024 compared to the prior year. This was driven primarily by lower average selling prices (pass-through of lower raw material costs and competitive pressures), partially offset by a 4% increase in sales volume in Q2 and 2% in H1.
- Profitability: Operating income increased 5% in Q2 but remained flat in H1. Net income declined 25% in Q2 and 19% in H1, largely due to a higher effective tax rate (44.7% in Q2 vs. 22.3% in Q2 2023) resulting from the election of "Bonus Depreciation" for a new facility, which limited the use of GILTI and FDII deductions.
- Segment Performance:
- Surfactants: Sales down 3% (Q2) and 10% (H1); Operating income up 13% (Q2) and 2% (H1) due to improved margins in Latin America and Asia.
- Polymers: Sales down 3% (Q2) and 6% (H1); Operating income down 17% (Q2) and 17% (H1) due to operational issues at the Millsdale, Illinois site and a catalyst write-off.
- Specialty Products: Sales down 29% (Q2) and 31% (H1); Operating income surged 94% (Q2) and 84% (H1) due to higher unit margins in the MCT product line.
- Unusual Items: A $3.5 million pre-tax charge was recorded in Q2 2024 related to a criminal social engineering scheme affecting an Asia subsidiary. Management expects a similar charge in Q3 2024.
Guidance, Outlook, and Risks
- Outlook: Management expects second-half EBITDA to improve versus the prior year, driven by volume growth and reduced operational expenses at the Millsdale site. Full-year Adjusted EBITDA growth and positive free cash flow are anticipated.
- Capital Expenditures: Full-year 2024 CapEx is estimated between $120.0 million and $140.0 million, primarily for the completion of the new alkoxylation plant in Pasadena, Texas.
- Risks & Contingencies:
- Environmental/Legal: Estimated range of possible environmental and legal losses is $20.8 million to $48.1 million; $20.8 million is currently accrued. Significant sites include Maywood (NJ), D'Imperio (NJ), and Wilmington (MA).
- Cybersecurity/Fraud: The Q2 social engineering fraud highlights risks related to IT system integrity and fraudulent activities. No material breach of customer data occurred, but the company expects additional near-term expenses.
- Operational: Flood events and operational disruptions at the Millsdale, Illinois plant impacted sales volume and margins in Q2.
Investor Verification Checklist
- Tax Rate Volatility: Verify the impact of the "Bonus Depreciation" election on the 2024 effective tax rate and future earnings.
- Fraud Investigation: Monitor the ongoing investigation into the Asia subsidiary social engineering scheme for potential additional charges in Q3 2024.
- Millsdale Operations: Assess the timeline for full recovery of the Millsdale, Illinois plant operations and the impact on Polymer segment margins.
- Environmental Accruals: Review updates on the Maywood and Wilmington site remediation costs, as actual liabilities could differ materially from the current $20.8 million accrual.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the minimum interest coverage ratio (3.50:1) and net leverage ratio (4.00:1).